Efficacy of 0.1% Tazarotene Cream for the Treatment of Photodamage
Authors:
- Tania J. PhillipsTPTania J. Phillips
- Alice B. GottliebAGAlice B. Gottlieb
- James J. LeydenJLJames J. Leyden
- Nicholas J. LoweNLNicholas J. Lowe
- Deborah A. Lew-KayaDLDeborah A. Lew-Kaya
- John SeftonJSJohn Sefton
- Patricia S. WalkerPWPatricia S. Walker
- John R. GibsonJGJohn R. Gibson
- 1 November 2002
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 138 (11) , 1486-1493
Abstract
Objective To determine the efficacy and safety of 0.1% tazarotene cream for the treatment of photodamage. Design A 24-week multicenter, double-blind, randomized, vehicle-controlled intervention study followed by a 28-week open-label extension. Setting Ambulatory patients in private and institutional practice. Patients Of 563 patients with facial photodamage, 91% and 86% completed the double-blind and open-label phases, respectively. In the double-blind phase, 20 of 283 tazarotene-treated patients and 1 of 280 vehicle-treated patients discontinued treatment owing to adverse events. Intervention Once-daily application of 0.1% tazarotene cream or nonmedicated vehicle cream to the face for 24 weeks. Then, all continuing patients received treatment with 0.1% tazarotene cream for another 28 weeks. Main Outcome Measures Primarily, fine wrinkling and mottled hyperpigmentation. Also, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, telangiectasia, actinic keratoses, overall integrated assessment of photodamage, global response to treatment, patients' overall assessment of photodamage, and plasma levels of tazarotenic acid. Results Compared with the vehicle, at week 24 tazarotene resulted in a significantly greater incidence of patients achieving treatment success (≥50% global improvement) and at least a 1-grade improvement in fine wrinkling, mottled hyperpigmentation, lentigines, elastosis, pore size, irregular depigmentation, tactile roughness, coarse wrinkling, and the overall integrated assessment of photodamage (P<.01). Additional clinical improvement occurred with continued tazarotene treatment and had not plateaued by week 52. Plasma tazarotenic acid concentrations did not exceed 0.71 ng/mL. Conclusions Once-daily applications of 0.1% tazarotene cream significantly reduced multiple signs of photodamage. Plasma levels of tazarotenic acid remained below those of endogenous retinoids.Keywords
This publication has 8 references indexed in Scilit:
- Tazarotene Cream for the Treatment of Facial PhotodamageArchives of Dermatology, 2001
- Photodamage pilot study: A double-blind, vehicle-controlled study to assess the efficacy and safety of tazarotene 0.1% gelJournal of the American Academy of Dermatology, 2000
- Isotretinoin improves the appearance of photodamaged skin: Results of a 36-week, multicenter, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2000
- Preliminary Observations on the Use of Topical Tazarotene to Treat Basal-Cell CarcinomaNew England Journal of Medicine, 1999
- The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term useJournal of the American Academy of Dermatology, 1997
- A review of skin ageing and its medical therapyBritish Journal of Dermatology, 1996
- Topical tretinoin for treatment of photodamaged skin. A multicenter studyArchives of Dermatology, 1991
- Topical tretinoin improves photoaged skin. A double-blind vehicle-controlled studyJAMA, 1988